Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the ...
Devdiscourse39m
Eli Lilly's Global Expansion Plan for Blockbuster Drug Mounjaro
Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...
Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
Senators say Kennedy must disclose details on drugmaker connections
Three senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to disclose what he and President ...
Investor's Business Daily on MSN42m
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.
Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints
Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...